Verona Pharma plc 2018 Annual Report And Accountsandnotice Of Agm

 
TIDMVRP 
 
   LONDON, March 22, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, is pleased to confirm that a hard copy of the 
Annual Report and Accounts for the year ended 31 December 2018 ("2018 
Annual Report and Accounts"), the Notice of Annual General Meeting and a 
Form of Proxy have been posted to Shareholders. 
 
   The Company confirms that a copy of its 2018 Annual Report and Accounts 
and Notice of Annual General Meeting are available online at 
www.veronapharma.com. The Notice of Annual General Meeting can also be 
found within the AIM Rule 26 section of the website. 
 
   The Annual General Meeting of Verona Pharma will be held at the London 
offices of Latham & Watkins LLP, 99 Bishopsgate, London EC2M 3XF at 
10.00 a.m. on 7 May 2019. 
 
   -Ends- 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine, is an investigational 
first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 
3 and 4 that is designed to act as both a bronchodilator and an 
anti-inflammatory agent in a single compound. Ensifentrine has been 
studied via the nebulized route of administration in clinical trials 
involving more than 800 subjects. The nebulized formulation of 
ensifentrine has significantly improved lung function, including 
enhanced peak FEV(1) , reduced lung hyperinflation and faster 
onset-of-action when used alone or as an add-on treatment to some of the 
most commonly used COPD therapies, including tiotropium (Spiriva(R) ), 
tiotropium/olodaterol fixed-dose combination, ipratropium, and 
albuterol. In addition, ensifentrine has shown anti-inflammatory effects 
in a standard challenge study with COPD-like inflammation in humans. 
Ensifentrine was well tolerated in these trials. Verona Pharma is 
developing ensifentrine for the treatment of COPD, cystic fibrosis and 
asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
Victoria Stewart, Director of Communications 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: [phone] 
Simon Conway / Natalie Garland-Collins             [e-mail] 
 
ICR, Inc. (US Media and Investor enquiries) 
Darcie Robinson                                    Tel: [phone] 
                                                    [e-mail] 
Stephanie Carrington                               Tel. [phone] 
                                                    [e-mail] 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 22, 2019 12:00 ET (16:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.